A2 Platinum 白金婴幼儿奶粉 4段
身边有好多朋友也想给孩子用4段补充营养，无奈孩子一喝奶粉就肚子胀气不消化
这其实是对普通奶粉中的A1型蛋白质不消化造成的
a2®4段这种只含有✨源初A2型蛋白质的奶粉
它温和不刺激，孩子自在消化好吸收，小肚子不遭罪
#带娃日常##轻奢新主义##帮你省钱赚钱[超话]#
身边有好多朋友也想给孩子用4段补充营养，无奈孩子一喝奶粉就肚子胀气不消化
这其实是对普通奶粉中的A1型蛋白质不消化造成的
a2®4段这种只含有✨源初A2型蛋白质的奶粉
它温和不刺激，孩子自在消化好吸收，小肚子不遭罪
#带娃日常##轻奢新主义##帮你省钱赚钱[超话]#
辉瑞评价口服PARP抑制剂TALZENNA® （talazoparib）联用XTANDI®（enzalutamide）治疗晚期去势耐受前列腺癌（mCRPC）的III期临床TALAPRO-2达主要终点——显著改善临床意义的影像无进展生存期（rPFS）！对照是安慰剂+XTANDI；关键次级终点是总体生存期，数据尚未成熟；其他次级终点，前列腺癌特异抗原（PSA）和总体反应率也有改善；XTANDI是雄激素受体抑制剂，是CRPC和mCSPC的标准治疗；TALZENNA或TALZENNA联用XTANDI方案均未批准，但TALAPRO-2的数据好的足以支撑FDA批准！
[十一]
TALAPRO-2，mCSPC阶段可以用过abiraterone，等待数据披露，这拥挤的赛道....
TALZENNA® first PARP inhibitor to demonstrate clinical benefit in combination with XTANDI® in metastatic castration-resistant prostate cancer (mCRPC)
Study achieves primary endpoint of radiographic progression-free survival
Robust, highly consistent efficacy demonstrated in mCRPC both with or without homologous recombination repair gene mutations.
The results of the primary endpoint exceeded the pre-specified hazard ratio of 0.696. (0.68 in PROpel)
TALAPRO-2，mCSPC阶段可以用过abiraterone，等待数据披露，这拥挤的赛道....
TALZENNA® first PARP inhibitor to demonstrate clinical benefit in combination with XTANDI® in metastatic castration-resistant prostate cancer (mCRPC)
Study achieves primary endpoint of radiographic progression-free survival
Robust, highly consistent efficacy demonstrated in mCRPC both with or without homologous recombination repair gene mutations.
The results of the primary endpoint exceeded the pre-specified hazard ratio of 0.696. (0.68 in PROpel)
✋热门推荐